Adc Therapeutics Sa · NYSE:ADCT
Adc Therapeutics Sa — Q3 2021 Earnings Presentation
10 slides from Adc Therapeutics Sa's earnings presentation, Nov 2, 2021
Slide 1: 3Q 2021 Earnings Call
3Q 2021 Earnings Call November 2, 2021
Slide 2: Forward-looking statements
Forward-looking statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics“, “we” or “us”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a reco
Slide 3: Agenda
Agenda 01 Chris Martin Introduction Chief Executive Officer Jennifer Herron Commercial Highlights 02 Chief Commercial Officer Joseph Camardo Clinical Highlights 03 Chief Medical Officer Jenn Creel Financial Update 04 Chief Financial Officer 3
Slide 4: Recent Highlights
Recent Highlights § Q3 2021 sales of $13.1m - first full quarter of launch, driven by strong execution and differentiated product profile ZYNLONTA® (loncastuximab § Marketing authorization application (MAA) validated by the European Medicines Agency (EMA) tesirine-lpyl) § Orphan Drug Designation in
Slide 5: Positive Momentum of ZYNLONTA Launch
Positive Momentum of ZYNLONTA Launch Encouraging performance driven by of differentiated product with broad applicability in the 3L+ Academic center support DLBCL patient population Resulting in higher total volume with equal account representation Q3 Net sales of as compared to the community Strong
Slide 6: Expanding the Potential of ZYNLONTA
Expanding the Potential of ZYNLONTA Additional trials in 2021 § Pivotal Ph 2 trial in FL open for enrollment LOTIS-5 § Dose-finding study of ZYNLONTA in combination ZYNLONTA with R-CHOP in 1L DLBCL + rituximab § ZYNLONTA in multiple combinations in NHL § Ph 3 trial in combination with rituximab LOTI
Slide 7: Cami Clinical Programs Advancing
Cami Clinical Programs Advancing Novel ADC targeting CD25 and regulatory T cells (Tregs) Relapsed or refractory Advanced Hodgkin lymphoma solid tumors § Phase 2 pivotal trial ongoing with § Phase 1b dose escalation trial of additional preliminary results Cami + pembrolizumab ongoing expected in 1H 2
Slide 8: Solid Tumor Franchise Leverages Validated ADC Platform
Solid Tumor Franchise Leverages Validated ADC Platform Cami ADCT-901 ADCT-601 Targeting CD25 Targeting KAAG-1 Targeting AXL § Phase 1b dose escalation trial of § Targeting advanced solid tumors § AXL overexpressed in many solid Cami + pembrolizumab ongoing with high unmet needs, including tumors - l
Slide 9: 3Q 2021 Financial Update (in $ millions)
3Q 2021 Financial Update (in $ millions) Balance Sheet September 30, 2021 June 30, 2021 Cash and cash equivalents $530.2 $371.9 Statement of Cash Flows Q3 2021 Q3 2020 Net cash used for operating activities $58.6 $44.3 Statement of Operations Q3 2021 Q3 2020 Product Revenue, Net $13.1 N/A Research &
Slide 10: Anticipated Milestones
Anticipated Milestones § 4Q 2021: - Initiate first line dosing trial of ZYNLONTA with R-CHOP ZYNLONTA® - Initiate ZYNLONTA trial in multiple combinations in NHL - Complete safety lead-in of the Phase 3 LOTIS-5 confirmatory trial in combination with rituximab - Continue enrollment in Phase 2 trial of